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Podocytes are highly differentiated cells that play an
important role in maintaining glomerular filtration barrier
integrity; a function regulated by small GTPase proteins of
the Rho family. To investigate the role of Rho A in podocyte
biology, we created transgenic mice expressing doxycycline-
inducible constitutively active (V14 Rho) or dominant-
negative Rho A (N19 Rho) in podocytes. Specific induction of
either Rho A construct in podocytes caused albuminuria and
foot process effacement along with disruption of the actin
cytoskeleton as evidenced by decreased expression of the
actin-associated protein synaptopodin. The mechanisms of
these adverse effects, however, appeared to be different.
Active V14 Rho enhanced actin polymerization, caused a
reduction in nephrin mRNA and protein levels, promoted
podocyte apoptosis, and decreased endogenous Rho A
levels. In contrast, the dominant-negative N19 Rho caused
a loss of podocyte stress fibers, did not alter the expression
of either nephrin or Rho A, and did not cause podocyte
apoptosis. Thus, our findings suggest that Rho A plays an
important role in maintaining the integrity of the glomerular
filtration barrier under basal conditions, but enhancement of
Rho A activity above basal levels promotes podocyte injury.
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Podocytes are highly differentiated cells that play an
important role in maintaining the integrity of the glomerular
filtration barrier.1–3 Their function is regulated by small
GTPases belonging to the Rho GTPase family.4–6 These small
GTPases act as molecular switches controlling activation of
multiple downstream effector molecules.7–10 Among their
pleiotropic actions, Rho-dependent signaling cascades mod-
ulate cellular morphology and actin polymerization, adhesion,
cell migration, proliferation, and apoptosis, as well as par-
ticipate in contractile responses.7–10 Although these actions
likely serve homeostatic functions under normal physiologic
conditions, Rho-dependent signaling cascades are highly
activated during inflammatory states, which, in turn, may
have pathological consequences.11–19 In this regard, a large
body of data implicate Rho GTPases in the pathogenesis
of disease processes in the kidney including glomerular
diseases.11–19 Moreover, a growing literature suggests that
Rho A may also play an important homeostatic function by
promoting a podocyte phenotype that stabilizes the glomer-
ular architecture.4–6 In this scenario, some basal level of
Rho A activity would be beneficial. In contrast, high levels of
Rho A activity induced by inflammatory processes may cause
podocyte injury.11–19 Indeed, recent studies provide strong
evidence that enhanced Rho A activity in podocytes has
adverse effects on glomerular filtration barrier function.20 The
mechanisms of altered glomerular permselectivity after Rho A
activation, however, have not been extensively characterized.
Moreover, there is little information on the role of basal Rho
A activity in regulating glomerular filtration barrier integrity.
In this study, we investigated the effect of modulating Rho A
activity in glomerular podocytes by creating transgenic (TG)
mice that expressed either a constitutively active Rho A (V14
Rho) or a dominant-negative Rho A (N19 Rho) specifically in
podocytes using a doxycycline-inducible system. Using these
TG mice, we found that either activation or inhibition of Rho A
in podocytes in vivo had adverse effects on podocyte function.
RESULTS
Creation of V14 Rho and N19 Rho TG mice
For the experiments, we utilized the Tet-On system,21 which
requires two TG mice for podocyte-specific expression. The
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first TG animal expresses the reverse tetracycline-controlled
transcriptional activator (rtTA) under the control of the
human podocin (NPHS2) promoter.22 The second TG mouse
expresses either V14 Rho or N19 Rho under the control of tet
operator sequence (tetO) and a minimal cytomegalovirus
(CMV) promoter (PminCMV).21 By breeding the two TG
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mice, animals are obtained that express both transgenes. In
these ‘double’ TG mice, treatment with doxycycline induces
transgene expression.
For the experiments, two independent TG lines were
established for each transgene. Figure 1a and d shows
expression of the hemagglutinin (HA)-tagged transgenes
after 1 week of doxycycline treatment by immunoblotting
for the HA epitope using glomerular preparations from
‘double’ TG mice (rtTA and either the V14 Rho or N19 Rho
transgenes) as well as ‘single’ TG mice (rtTA, v14Rho, or N19
Rho transgenes) and non-TG mice. Expression of either the
V14 Rho or N19 Rho protein was detectable by immuno-
blotting in ‘double’ TG mice but not in ‘single’ TG or non-
TG mice (Figure 1a and d). In the absence of doxycycline, the
Rho proteins were not detected in non-TG or ‘single’ TG or
‘double’ TG mice (not shown).
Figure 1b and e shows tissue-specific expression of the V14
Rho and N19 Rho by reverse transcriptase-PCR (RT-PCR)
using mRNA prepared from mice treated with doxycycline.
As shown in the top panel of Figure 1b and e, a RT-PCR
product of the appropriate size was detected in kidney cortex
and glomerular preparations from ‘double’ TG mice. No RT-
PCR products were detected in other tissues from the
‘double’ TG mice. The glyceraldehyde 3-phosphate dehydro-
genase RT-PCR reaction confirmed that the reverse tran-
scriptase reaction was successful in the tissues examined
(lower panel). In data not shown, expressions of the V14 Rho
or N19 Rho transgenes were: (1) not detected by RT-PCR in
any of the tissues from other doxycycline-treated ‘single’ TG
mice and non-TG controls, and (2) not detected by RT-PCR
in ‘double’ TG mice in either the absence of doxycycline
treatment or in the absence of a RT reaction.
We next determined cell-specific expression of the
transgene. For these studies, tissue sections were stained for
expression of the HA-tagged V14 Rho or N19 Rho transgenes
(rhodamine) and the podocyte marker podocalyxin (fluor-
escein). As shown in Figure 1c and f, only podocalyxin was
detected in ‘single’ TG mice treated with doxycycline. In
contrast, the lower panels show that both the HA epitope
and podocalyxin were detected in ‘double’ TG mice treated
with doxycycline. Merging the two images suggested that
the HA epitope and podocalyxin shared a similar cellular
distribution. In data not shown, the HA epitope was not
detected in rtTA ‘single’ TG mice and non-TG controls in the
presence of doxycycline or in ‘double’ TG mice in the absence
of doxycycline.
Effect of transgenes on albuminuria
For these studies, ‘double’ TG mice and controls (‘single’ TG
and non-TG mice) were treated with doxycycline or vehicle
for 2 weeks and before measuring albuminuria. Experimental
results were similar using the progeny from the independent
lines and these data were combined for the analyses.
Induction of either the V14 Rho transgene (Figure 2a) or
the N19 Rho transgene (Figure 2b) caused a significant
increase in albuminuria in ‘double’ TG mice compared
with controls. As shown in Table 1, similar results were seen
when albuminuria data were expressed as mg albumin per mg
creatinine. Moreover, the increase in albuminuria after
transgene induction was reversible 2–4 weeks after discon-
tinuing doxycycline treatment (Table 2).
We next determined the effects of more prolonged
transgene induction on albuminuria. For these studies, mice
were treated for 6 weeks with doxycycline, and albuminuria
was examined at baseline and 2, 4, and 6 weeks after
doxycycline treatment. As shown in Figure 2c, induction of
V14 Rho caused a progressive increase in albuminuria over
the 6-week treatment period compared with control animals.
By the 6-week time point, albuminuria was significantly
increased compared with the 2-week time point in V14 Rho
‘double’ TG mice. Induction of the N19 Rho transgene also
caused an increase in albuminuria compared with control
animals (Figure 2d). The increase in albuminuria, however,
was not significantly different during doxycycline treatment in
N19 Rho ‘double’ TG mice at the three time points examined.
Glomerular histomorphology and glomerular ultrastructure
Light microscopic examination of kidney sections revealed
minimal abnormalities (Figure 3a–c). Transmission electron
microscopy revealed a few areas of foot process (FP)
flattening in the control mice (Figure 3d and g). In contrast,
large areas of FP effacement involving the majority of
glomeruli available for examination were detected in both
V14 Rho (Figure 3e and h) and N19 Rho (Figure 3f and i)
Figure 1 |Creation of transgenic (TG) mice and induction of the transgene. In a and d, induction of the N19 Rho and V14 Rho transgenes,
respectively, was investigated by immunoblotting for the hemagglutinin (HA) epitope in non-TG mice, ‘single’ TG mice, and ‘double’ TG mice
after doxycycline treatment. Both transgenes were induced by doxycycline in ‘double’ TG mice but not in control mice. Transgene expression
was not detected by immunoblotting in the absence of doxycycline (data not shown). rtTA, reverse tetracycline-controlled transcriptional
activator. In b and e, tissue-specific expression of the transgenes was investigated by reverse transcriptase-PCR (RT-PCR) in ‘double’ TG mice
after treatment with doxycycline using transgene-specific primers. A RT-PCR product was detected in both kidney cortex and isolated
glomerular preparations from N19 Rho ‘double’ TG mice and V14 Rho ‘double’ TG mice as indicated. No RT-PCR products were detected in
other tissues from the ‘double’ TG mice. The glyceraldehyde-3-phosphate dehydrogenase (GAPDH) control confirmed that the RT reaction
was successful in the tissues examined. No RT-PCR products were obtained in any tissues from ‘double’ TG mice in either the absence of
doxycycline treatment or in the absence of an RT reaction (not shown). Similarly, no RT-PCR products were obtained in any tissues from
doxycycline-treated ‘single’ TG or non-TG mice (not shown). B, brain; G, glomeruli; H, heart; K, kidney cortex; Li, liver; Lu, lung; M, muscle
(skeletal); S, spleen. In c and f, tissue sections were stained for expression of the HA-tagged transgenes and the podocyte marker podocalyxin
as indicated. As shown in the upper panels, podocalyxin, but not the HA epitope, was detected in ‘single’ TG mice treated with doxycycline.
In contrast, the lower panel shows that both the HA epitope and podocalyxin were detected in ‘double’ TG mice treated with doxycycline.
When the two images are merged, the HA epitope and podocalyxin had a similar cellular distribution in the ‘double’ TG mice.
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‘double’ TG mice. To quantitate the severity of FP effacement,
we assessed the number of patent slit diaphragms per mm of
glomerular basement membrane. There was a significant
decrease in the number of patent slit diaphragms per mm of
glomerular basement membrane in both V14 Rho ‘double’
TG mice (2.25±0.21 (controls) vs. 1.24±0.23 (V14 Rho
‘double’ TG); Po0.01) and N19 Rho ‘double’ TG mice
(2.19±0.20 (controls) vs. 1.22±0.25 (N19 Rho ‘double’ TG);
Po0.01). The light microscopic and ultrastructural findings
were similar in ‘double’ TG mice and controls after either 2
or 6 weeks of doxycycline treatment.
Effect of the transgenes on actin polymerization
Rho GTPases are important regulators of actin polymeriza-
tion,7 and maintenance of the actin cytoskeleton plays a critical
role in sustaining glomerular filtration barrier function.4–6 To
investigate the effect of Rho A on actin polymerization, we
introduced V14 Rho or N19 Rho into cultured podocytes using
protein transduction23 by tagging the proteins with the TAT
(transactivator of transcription) human immunodeficiency
virus protein sequence (V14 Rho(þ ) or N19 Rho(þ )). Cell-
impermeable proteins lacking the TAT sequence were used as
controls (V14 Rho() or N19 Rho()). For the experiments,
cultured podocytes were treated with V14 Rho or N19 Rho
TAT proteins and then actin polymerization was monitored
by phalloidin staining (rhodamine). As shown in Figure 4a, a
few stress fibers were seen in podocytes treated with a control
Rho A protein lacking the TAT sequence. In podocytes treated
with V14 Rho(þ ), the number of stress fibers was increased
(Figure 4b), whereas in cells treated with N19 Rho(þ ), the
number of stress fibers was reduced (Figure 4c). Quantitation
of actin polymerization (F actin) is shown in Figure 4d.
V14 Rho(þ ) induced a significant increase in actin poly-
merization compared with control podocytes. In contrast,
actin polymerization was significantly decreased by treatment
with N19 Rho(þ ) compared with either control podocytes
or podocytes treated with V14 Rho(þ ). Podocyte morphol-
ogy was similar in untreated podocytes and podocytes treated
with control TAT proteins (not shown).
Effect of the transgenes on synaptopodin expression
Synaptopodin is an actin-associated protein that is expressed
exclusively by podocytes in the kidney.24 To determine if the
effects of the transgenes on actin polymerization (Figure 4)
affected synaptopodin expression in vivo, we first measured
glomerular synaptopodin levels by immunoblotting in mice
treated with doxycycline for 6 weeks. As shown in Figure 5a,
synaptopodin levels were decreased by induction of either
Table 2 | Albuminuria (lg albumin per 24 h)
V14 Rho studies N19 Rho studies
Controls ‘Double’ TG Controls ‘Double’ TG
Baseline 48±6.6 52±7.3 31±6.2 58±9.1
2 Weeks of doxycycline 40±5.2 112±26*,w 27±10 196±61*
2 Weeks after doxycycline 28±19 24±8.6z 27±10 49±18
4 Weeks after doxycycline 35±19 31±17z 32±19 11±7.5z
Abbreviation: TG, transgenic.
*Po0.001 vs. doxycycline-treated controls.
wPo0.01 vs. baseline V14 ‘double’ TG mice.
zPo0.05 vs. ‘double’ TG after 2 weeks of doxycycline treatment.
Table 1 | Albuminuria (lg albumin/mg creatinine)
V14 Rho studies N19 Rho studies
Controls ‘Double’ TG Controls ‘Double’ TG
Baseline 44±19 25±13 37±11 25±4
Doxycycline 36±8 108±36*,w 36±5 178±54**,w
Abbreviation: TG, transgenic.
*Po0.025 or **Po0.05 vs. doxycycline-treated controls. wPo0.05 vs. ‘double’ TG at
baseline.
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Figure 2 | Effect of transgene induction on albuminuria. In a
and b, albuminuria was measured after 2 weeks of treatment in
both N19 Rho ‘double’ transgenic (TG) mice and V14 Rho ‘double’
TG mice as well as controls (‘single’ TG and non-TG mice).
Treatment with doxycycline significantly increased albuminuria in
(a) V14 Rho and (b) N19 Rho ‘double’ TG mice compared with
‘double’ TG mice at baseline or compared with controls at either
baseline or after treatment with doxycycline. In c and d, mice
were treated for 6 weeks with doxycycline and albuminuria was
measured at the 2-, 4-, and 6-week time points. (c) In V14 Rho
‘double’ TG mice, albuminuria was increased during doxycycline
treatment compared with controls and tended to increase over
time. At the 6-week time point, albuminuria was significantly
increased compared with the 2-week time point in V14 Rho
‘double’ TG animals. Albuminuria was also increased in N19 Rho
‘double’ TG mice compared with controls after doxycycline
treatment at all time points examined, but tended to remain
relatively stable over the treatment period. Eight to 16 mice were
studied per group. zPo0.05 vs. ‘double’ TG at baseline, *Po0.01
vs. ‘double’ TG at baseline, yPo0.05 vs. controls after treatment
with doxycycline, fPo0.01 vs. controls after treatment with
doxycycline, wPo0.001 vs. controls after treatment with
doxycycline, zPo0.01 vs. ‘double’ TG at 2 weeks.
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V14 Rho or N19 Rho compared with controls. The podocyte
protein podocalyxin was not affected by induction of either
transgene. Quantitation of synaptopodin protein and mRNA
levels is shown in Figure 5b and c, respectively. Synaptopodin
protein levels were decreased at both ‘double’ TG lines
compared with controls. A similar pattern was seen for
synaptopodin mRNA levels at the 6-week time point. Despite
the marked reduction in synaptopodin protein levels by
immunoblotting, synaptopodin was detectable by immuno-
histochemistry in both control mice and ‘double’ TG mice
(Figure 5d), although the intensity of the immunofluorescence
tended to be decreased in ‘double’ TG animals. In V14 Rho
‘double’ TG mice, synaptopodin staining also tended to be more
granular (Figure 5d, bottom panel) compared with the linear
staining observed in N19 Rho ‘double’ TG mice and controls
(Figure 5d, top and middle panels). We also investigated
synaptopodin expression at the 2-week time point. As shown in
Supplementary Figure S1 online, synaptopodin mRNA and
protein levels were both decreased in N19 Rho ‘double TG mice
after 2 weeks of doxycycline treatment. In contrast, synaptopo-
din mRNA and protein levels were better preserved at this time
point in V14 Rho ‘double’ TG mice, suggesting that the tempo
of synaptopodin loss was delayed in these animals.
Effect of the transgenes on expression of Rho A
The Rho GTPase family includes members belonging to the
Rho, Rac, and cdc42 GTPases.25 In podocytes, the Rho A
protein is stabilized by interacting with the podocyte protein
synaptopodin.5 We, therefore, determined if decreased synap-
topodin levels in ‘double’ TG mice affected expression of Rho
GTPase family members in enriched glomerular preparations
after 6 weeks of doxycycline treatment. As shown in Figure 6a
and b, Rho A levels were unaffected by transgene induction in
N19 Rho ‘double’ TG animals. In contrast, Rho A levels were
significantly decreased in V14 ‘double’ TG mice compared
with either controls or N19 Rho ‘double’ TG animals. As
shown in the inset to Figure 6b, the changes in Rho A protein
levels represented endogenous Rho A expression because
longer exposure of the immunoblots detected expression of the
slightly larger Rho A transgenes. Rac1 levels were not changed
by transgene induction (Figure 6a) and cdc42 was difficult to
detect in the glomerular preparations (not shown).
Control
Control
Control
V14Rho ‘double’ TG N19Rho ‘double’ TG
N19Rho ‘double’ TG
N19Rho ‘double’ TG
V14Rho ‘double’ TG
V14Rho ‘double’ TG
US
US
US
US
US
US
US
US
US
US
US
US
Figure 3 |Renal histology. Glomerular histology in (a) controls, (b) V14 Rho ‘double’ transgenic (TG) mice, and (c) N19 Rho ‘double’ TG mice
2 weeks after treatment with doxycycline. Glomerular histology was similar in all groups at the light microscopic level. (d–i) Glomerular
ultrastructure in controls, V14 Rho ‘double’ TG mice, and N19 Rho ‘double’ TG mice 2 weeks after treatment with doxycycline. Low-power
views are shown in d–f and higher-magnification images are shown in g–i. In both N19 Rho and V14 Rho ‘double’ TG mice, large areas of
foot process (FP) effacement (arrows) were detected involvingB40% of the glomerular basement membrane (GBM) length. In contrast, FPs
were well preserved in control mice treated with doxycycline, although a few areas of FP flattening were observed. US, urinary space.
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Effect of Rho A on podocyte apoptosis
Rho A plays an important role in regulating cell death, in
part, by inhibiting the prosurvival and anti-apoptotic
phophatidylinositol-3-kinase (PI3K)/Akt pathway.25–27 This
negative regulatory effect is mediated by the downstream Rho
A effectors Rho kinases or ROKs,25 which phosphorylate and
activate PTEN (phosphatase and tensin homolog deleted on
chromosome ten).28 PTEN, in turn, dephosphorylates and
Control
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V14 Rho
V14 Rho
N19 Rho
N19 Rho
806040
*
20
Percent cellular area binding phalloidin
0
†
Figure 4 | Effect of V14 Rho and N19 Rho on actin polymerization in podocytes. (a) A few stress fibers are seen in podocytes treated
with control proteins. (b) In contrast, V14 Rho(þ ) treatment enhanced the number of stress fibers, whereas (c) treatment with N19 Rho(þ )
caused a decrease in stress fiber formation. Quantitation of the percent cellular area binding phalloidin is shown in d. There was a significant
increase in the percent cellular area binding phalloidin in V14 Rho(þ )-treated podocytes compared with cells treated with either control
proteins or N19 Rho(þ ). Treatment with N19 Rho(þ ) significantly decreased phalloidin binding compared with cells treated with either
control proteins or V14 Rho(þ ). *Po0.01 vs. cultured podocytes treated with either control TAT (transactivator of transcription) proteins or
N19 Rho(þ ), wPo0.01 vs. cultured podocytes treated with either control TAT proteins or V14 Rho(þ ).
Synaptopodin
+ + + + + + + + +
Doxycycline
Control
Controls
‘Double’  TG
† †
Controls
‘Double’  TG
N19 ‘double’  TG
N19Rho study V14Rho study N19Rho study
1.4
1.2
1.0
0.8
0.6
0.4
0.2
0.0
0.8
0.6
0.4
0.2
0.0
R
el
at
ive
 e
xp
re
ss
io
n 
of
 s
yn
ap
to
po
di
n 
m
RN
A
D
en
si
to
m
et
ry
 u
ni
ts
 (s
yn
ap
top
od
in/
ac
tin
)
*
**
V14Rho study
V14 ‘double’  TG
Podocalyxin
Actin
N19
V14
rtTA +
+
+ + + +
+ + +
++++++––
––
– – – – –
– – –
Figure 5 | Effect of the Rho transgenes on synaptopodin and podocalyxin expression. (a) Representative immunoblots of
synaptopodin and podocalyxin protein levels in enriched glomerular preparations after 6 weeks of doxycycline treatment. Synaptopodin
levels were difficult to detect in both N19 Rho and V14 Rho ‘double’ transgenic (TG) mice compared with controls. In contrast, podocalyxin
levels were not changed in any of the groups. rtTA, reverse tetracycline-controlled transcriptional activator. Quantitation of the
immunoblots is shown in b. Induction of the Rho A transgenes in ‘double’ TG mice significantly reduced glomerular synaptopodin protein
levels compared with controls. As shown in c, a similar reduction in synaptopodin mRNA levels was seen in both N19 Rho and V14 Rho
‘double’ TG mice compared with controls. In d, synaptopodin was detected by immunohistochemistry in all groups, although the
immunofluorescence tended to be reduced in the ‘double’ TG mice. Moreover, the staining appeared more granular in the V14 ‘double’ TG
animals. Four to 6 samples were studied per group. *Po0.05 or **Po0.01 vs. controls, wPo0.001 vs. controls.
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inactivates Akt.25 To investigate the effect of Rho A on
podocyte apoptosis in vitro, we treated cultured podocytes
with V14 Rho or N19 Rho TAT proteins and then measured
apoptosis as described in the Materials and Methods section.
As shown in Figure 7a, V14 Rho(þ ) enhanced podocyte
apoptosis compared with V14 Rho(), and this apoptotic
effect was blocked by the Y27632. In contrast, N19 Rho(þ )
had no significant effect on apoptosis of cultured podocytes
compared with cells treated with N19 Rho() (7.4±3.2 (N19
Rho(þ )) vs. 7.2±1.7 (N19 Rho()) percent apoptosis above
baseline; P¼NS). To assess PTEN phosphorylation levels, we
immunoprecipitated PTEN and then immunoblotted for
PTEN and phosphothreonine (Figure 7b). Densitometric
quantitation of the immunoblots is shown in Figure 7c.
Phospho-PTEN levels were significantly increased in cultured
podocytes 10 and 30min after treatment with V14 Rho(þ )
compared with cells treated with V14 Rho().
To determine if Rho A activation caused podocyte apoptosis
in vivo, we assessed both podocyte number and podocyte
apoptosis after 6 weeks of doxycycline treatment. We were,
however, unable to detect podocyte apoptosis, and the number
of podocytes per glomerular profile was similar in controls and
either N19 Rho ‘double’ TG mice (8.1±0.4 (controls) vs.
8.5±0.5 (N119Rho); P¼NS) or V14 Rho ‘double’ TG mice
(8.4±0.2 (controls) vs. 8.1±0.2 (N119Rho); P¼NS).
Effect of transgene induction on glomerular nephrin
expression
The podocyte protein nephrin plays a critical role in
maintaining the integrity of the glomerular filtration
barrier,29–31 and its expression is decreased in some,32–40
although not all,32 proteinuric glomerular diseases. In
addition to its structural role, nephrin is also a signaling
molecule.27,41,42 In this regard, nephrin may inhibit podocyte
apoptosis by activating the prosurvival PI3K/Akt pathway.25,41
In this scenario, a decrease in glomerular nephrin expression
might promote apoptosis of glomerular podocytes. We,
therefore, measured nephrin mRNA levels using quantitative
RT-PCR and glomerular mRNA prepared from mice treated
for 6 weeks with doxycycline. As shown in Figure 8a,
induction of the V14 Rho transgene caused a reduction in
nephrin mRNA levels. In contrast, nephrin mRNA levels were
similar in N19 ‘double’ TG mice compared with controls.
Figure 8a and b shows representative immunoblots of nephrin
protein levels in glomerular preparations from N19 Rho and
V14 Rho ‘double’ TG mice and controls (‘single’ TG and non-
TG mice) treated for 6 weeks with doxycycline. Quantitation
of the immunoblots is shown in Figure 8d. There was a
significant decrease in nephrin protein levels in V14 Rho
‘double’ TG compared with controls. In contrast, nephrin
protein levels were similar in N19 Rho ‘double’ TG compared
with control animals. Similar results were obtained at the
2-week time point (Supplementary Figure S2 online). With
longer exposure nephrin protein appears as a doublet.
DISCUSSION
In this study, we found that both Rho A activation and Rho A
inhibition, specifically in glomerular podocytes, caused
albuminuria and FP effacement. These data, taken together
with recently published studies,20 suggest that Rho activity in
podocytes must be tightly regulated to maintain podocyte
function. Given that excessive Rho GTPase activity likely
contributes to glomerular damage in disease states,11–19 the
observation that Rho A inhibition also promotes podocyte
injury has implications for treatment strategies in glomerular
disease processes. In this regard, chemically distinct ROK
inhibitors attenuate renal damage in a variety of experimental
models.11–19 Moreover, ROK inhibition reduces glomerular
injury in animal models without adversely affecting glomer-
ular filtration barrier function.11–15,18,19 In contrast, Rho A
inhibition caused albuminuria and FP effacement in this
study. Although we cannot exclude ‘off-target’ effects of
transgene overexpression, these data are consistent with the
notion that treatment strategies that inhibit Rho A may be
difficult to employ clinically because of the potential for
damaging the integrity of the glomerular filtration barrier,
whereas strategies that target downstream effectors of Rho A
such as ROKs may attenuate the detrimental effects of
Doxycycline
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Figure 6 | Effect of the Rho transgenes on expression of Rho
GTPase family members. In a, Rho A levels were decreased in
V14 Rho ‘double’ transgenic (TG) mice compared with controls.
In contrast, Rac1 expression was similar in all groups examined.
rtTA, reverse tetracycline-controlled transcriptional activator.
Quantitation of the Rho A immunoblots is shown in b. Induction
of the V14 Rho transgene in ‘double’ TG mice significantly reduced
glomerular Rho A protein levels compared with controls as well as
N19 Rho ‘double’ TG mice. The changes in Rho A protein levels
represented endogenous Rho A expression because longer
exposure of the immunoblots detected expression of the slightly
larger Rho A transgenes (inset). Nine samples were studied per
group, *Po0.05 vs. V14 Rho controls or N19 Rho ‘double’ TG mice.
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excessive Rho A activity in glomerular diseases without
adversely affecting glomerular filtration barrier function.
Although both Rho A activation and Rho A inhibition
promoted albuminuria and FP effacement, the mechanisms
appeared to be different. For example, V14 Rho reduced
glomerular nephrin expression, increased the number of
stress fibers, and promoted podocyte apoptosis. In contrast,
N19 Rho had little effect on glomerular nephrin levels or
podocyte apoptosis but reduced stress fiber formation. These
findings suggest that the mechanisms of proteinuria induced
by Rho A activation are different from the mechanisms that
promote proteinuria during Rho A inhibition. In this regard,
a major function of glomerular podocytes is to provide
structural support to the glomerular tuft.43 By modulating
actin polymerization, Rho GTPases likely play a pivotal role
in regulating podocyte morphology that, as growing
literature suggest, is important for maintaining the integrity
of the glomerular filtration barrier.4–6 In proteinuric renal
diseases, a reduction in the activity of Rho GTPases may lead
to a phenotypic change in the glomerular podocyte
characterized by a loss of stress fibers and enhanced
formation of lamellipodia and filopodia as a result of
activation of the Rho GTPase family members Rac1 and
cdc42.4–6 Indeed, in humans with minimal change disease,
there are few light microscopic abnormalities, but the
podocyte undergoes a phenotypic switch characterized by
FP effacement and, in some patients, microvillus protrusions
on the apical surface reminiscent of filopodia.32 Despite this
apparent change in podocyte morphology, expression of
podocyte proteins such as nephrin32 are not changed in
minimal change disease, with the exception of the actin-
associated protein synaptopodin that may be decreased.44
Although we did not detect microvillus protrusions in this
study, the N19 Rho ‘double’ TG mice did exhibit: (1) normal
light microscopic findings, (2) FP effacement, and (3)
preservation of nephrin expression despite a significant
decrease in glomerular synaptopodin levels. Thus, activation
of the N19 Rho transgene resulted in many of the features of
patients with minimal change disease.
In contrast to Rho A inhibition, enhanced Rho A activity
stimulated actin polymerization as well as reduced glomer-
ular nephrin expression and caused apoptosis of cultured
podocytes. Although we were unable to demonstrate that
induction of V14 Rho in podocytes caused either apoptosis
or a decrease in podocyte number in vivo, in glomerular
diseases, podocyte apoptosis is an important mechanism
leading to a decrease in podocyte number.32,43,45–47 Although
the mechanisms that promote podocyte apoptosis are likely
complex, the prosurvival PI3K/Akt pathway protects podo-
cytes from apoptosis;25–27 and PI3K activity is negatively
regulated by Rho A through its downstream effector ROK by
phosphorylating and activating the Akt inhibitor PTEN.25
Moreover, the decrease in glomerular nephrin expression
following induction of the V14 Rho transgene may also
promote apoptosis of glomerular podocytes because nephrin
directly stimulates the prosurvival PI3K/Akt pathway.25,41
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Figure 7 | Effect of V14 Rho(þ ) on podocyte apoptosis. In a, treatment with V14 Rho(þ ) significantly increased podocyte apoptosis
compared with cells treated with V14 Rho(), and Y27632 significantly reduced podocyte apoptosis induced by V14 Rho(þ ). Immunoblotting
of the hemagglutinin (HA)-tagged V14 Rho proteins in either culture medium or podocyte lysates is shown in the inset. The HA-tagged
V14 Rho(þ ) was effectively transduced into cultured podocytes. There is a slight difference in molecular size of V14 Rho(þ ) and V14 Rho()
due to the presence or absence of the TAT (transactivator of transcription) sequence. In b, total PTEN (phosphatase and tensin homolog deleted
on chromosome ten) and phospho-PTEN levels were assessed in immortalized podocytes after treatment with V14 Rho(þ ) or V14 Rho().
Densitometric quantitation of the immunoblots is shown in c. Phospho-PTEN levels were significantly increased in cells treated with
V14 Rho(þ ) at the 10- and 30-min time points. Four to 7 samples were studied per group for the apoptosis experiments. Four to 5 samples
were studied per group for the immunoblotting studies. *Po0.001 vs. cells treated with V14 Rho() and vehicle, wPo0.01 vs. cells treated with
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Given that cellular outcome is likely dependent on differential
activation of signaling pathways that promote either cell
survival or apoptosis, a decrease in PI3K/Akt signaling might
alter this balance and promote podocyte apoptosis that, some
investigators contend, may cause instability of the glomerular
tuft and glomerulosclerosis.32 Indeed, recent studies suggest
that high levels of Rho activation in podocytes promote focal
glomerulosclerosis,20 whereas lower levels of Rho activation
cause FP effacement without light microscopic abnormal-
ities.20 Although we did not observe glomerulosclerosis in our
study, it is possible that the level of Rho activation in our
experiments may have been insufficient to promote sclerosis.
Alternately, differences in experimental design including
genetic background of the mice may have contributed to
the lack of glomerulosclerosis observed in the present
experiments compared with published studies.20
Last, both Rho A activation and Rho A inhibition caused a
reduction in glomerular synaptopodin expression in ‘double’
TG mice after 6 weeks of treatment with doxycycline.
Synaptopodin stabilizes Rho A protein levels by a protein
interaction between Rho A and synaptopodin that, in turn,
prevents Rho A from interacting with the ubiquitin ligase
Smurf1 and proteosomal degradation.5 We, therefore, inves-
tigated the effect of decreased synaptopodin expression on the
level of Rho GTPase proteins. We found that endogenous
Rho A protein levels were decreased in V14 Rho ‘double’ TG
mice, consistent with the notion that synaptopodin stabilizes
the Rho A protein. In contrast, Rho A protein levels were not
affected by expression of the N19 Rho transgene despite a
decrease in synaptopodin levels in N19 Rho ‘double’ TG mice.
Although we can only speculate on mechanism, the
protein–protein interaction between Rho A and Smurf1 pre-
ferentially favors an interaction between inactive Rho A proteins
(guanosine diphosphate-bound Rho A) such as the dominant-
negative N19 Rho construct.48 Indeed, V14 Rho binds Smurf1
poorly or not at all.48 Based on these observations, we speculate
that induction of N19 Rho competes with endogenous inactive
Rho A proteins (guanosine diphosphate-bound Rho A) and,
in turn, competitively antagonizes degradation of endogen-
ous Rho A in N19 Rho ‘double’ TG mice. This competitive
antagonism does not occur in the V14 Rho ‘double’ TG mice
and, as a result, a decrease in synaptopodin levels in these
animals enhances degradation of endogenous Rho A.
In summary, we found that either Rho A activation or Rho
A inhibition had similar adverse effects on glomerular
filtration barrier function and reduced podocyte synaptopo-
din expression, but the mechanisms of these detrimental
effects appeared to be different. Enhanced Rho A activity
increased actin polymerization as well as caused a reduction
in glomerular nephrin expression and promoted podocyte
apoptosis. In contrast, inhibition of Rho A caused a loss of
podocyte stress fibers but did not alter glomerular nephrin
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expression and did not cause podocyte apoptosis. These data
suggest that some basal level of Rho A activity has beneficial
effects on podocytes, perhaps by stabilizing the glomerular
architecture. The level of Rho A activity, however, must be
tightly regulated because enhancing Rho A activity above
basal levels also has adverse effects on glomerular filtration
barrier function. Taken together with published studies,11–20
these findings suggest that Rho A plays an important role in
modulating the integrity of the glomerular filtration barrier,
both under basal conditions and during disease states.
MATERIALS AND METHODS
Materials
Alexa Fluor 568 phalloidin was obtained Molecular Probes (Eugene,
OR), the urine albumin and creatinine kits were obtained from
AssayPro (St Charles, MO) and Exocell (Philadelphia, PA), respec-
tively, the ROCK inhibitor Y2763238 was obtained from Calbiochem
(La Jolla, CA), and the TAT protein DNA constructs49 were obtained
from Becker-Hapak (Washington University, St Louis, MO).23
Creation of inducible V14 Rho and N19 Rho transgenes
The V14 Rho and N19 Rho transgenes were created by subcloning
a fragment of the HA-tagged TAT constructs into a previously
described construct.50
PCR
Screening for TG mice and expression of transgene mRNA were
performed using PCR or RT-PCR, respectively, and the primer pairs
50-AAGGACCAGTTCCCAGAGGT-30 and 50-GAAATTGGACAGCA
AGAAAG-30.
Experimental procedures
The following experimental procedures were performed as previously
described:37,38,50–53 (1) culture of mouse podocytes and treatment
with TAT proteins, (2) creation of FVB/NJ TG mice and induction of
the transgenes, (3) light, electron microscopy and quantitation of slit
diaphragm patency, (4) isolation of glomerular preparations, (5)
immunoblotting and immunohistochemistry, (6) detection of
apoptosis (in vivo and in vitro), (7) quantitation of glomerular
podocytes, (8) immunoprecipitation of PTEN, (9) real-time
quantitative RT-PCR, and (10) quantitation of polymerized actin
in cultured podocytes. All animal procedures were approved by the
Animal Care and Use Committee of Duke University Medical Center.
Additional details are provided in the Supplementary Section.
Statistical analysis
Data are presented as the mean±s.e.m. For comparison between
two groups, statistical significance was assessed by a t-test using the
InStat computer program (GraphPad Software, San Diego, CA). For
comparisons between more than two groups, statistical analysis was
performed using a one-way analysis of variance followed by a
Bonferonni multiple comparisons post test54 using the InStat program.
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